A faster review means there may soon be a novel therapy for the skin manifestations of lupus for the first time in a half-century.

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

In a recent study of people with cutaneous lupus erythematosus (CLE, skin disease in someone with lupus), researchers found that having a family history of CLE was a significant predictor of CLE.

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to EMD Serono's investigational drug ...

Survey results indicated that cutaneous lupus erythematosus (CLE) significantly affects quality of life (QOL) independently and additively in patients with systemic lupus erythematosus (SLE), with ...

Medically reviewed by David Ozeri, MD Key Takeaways Lupus can cause hives in about 10% of cases.Hives in lupus last for more ...

The FDA has granted breakthrough therapy designation to enpatoran for lupus with active skin manifestations, according to a ...

EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment. Cutaneous lupus erythematosus is a common manifestation of ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy ...

Please provide your email address to receive an email when new articles are posted on . Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of ...